CVM CEL SCI CORP Insider Trading

CEO Geert R Kersten bought 300.0K shares of CVM at $1.20 on 2026-05-14, increasing holdings +2598.1% to 311.5K shares.

Geert R Kersten, CEO of CEL SCI CORP, purchased 300,000 shares at $1.20 for $360,000.00, a substantial accumulation that grew his stake from 11,547 shares to 311,547 shares. The current stock price of $1.60 is -88.1% from the 52-week high of $13.48, and the stock has declined -67.7% over the past 30 days and -66.5% over 90 days. At this same ticker, his prior buy on 2026-01-22 returned -8.8% in 30 days, and his 2025-12-04 purchase returned -13.6% in 30 days, while earlier buys on 2025-07-25 and 2024-05-08 showed positive 90-day returns of +31.2% and +2403.6% respectively. The company reported quarterly revenue of $77,403.00 with net income of $-5,469,446.00, reflecting unprofitability over its most recent full fiscal year, though annual revenue growth was +65.4% year-over-year. This large open-market purchase by the CEO during a period of severe stock depreciation and negative profitability warrants close attention to the company's operational trajectory and the rationale behind this capital deployment.

CEO Geert Kersten buys 100,000 shares at $1.19 as stock trades 91% below 52-week high; fifth open-market purchase in two years despite mixed track record.

Geert Kersten, CEO of CEL SCI CORP, deployed over $119,000 to acquire 100,000 shares on the open market, expanding his direct stake by roughly 82 percent and marking his fifth open-market purchase at this company in just over two years. The stock is trading well below its 52-week high and has declined sharply over the past three months, presenting a classic opportunity for insider accumulation during weakness. However, Kersten's prior trading record at CVM is decidedly mixed: of his four previous open-market purchases, two were followed by stock appreciation over the subsequent quarter while two were preceded by declines, suggesting his timing at this company has been inconsistent. The company itself remains unprofitable with negative earnings, though annual revenue showed growth compared to the prior year—a thin positive in a otherwise challenged financial profile. This is noteworthy not for "conviction" but for pattern: a CEO who continues to buy his own company shares despite a mixed track record and the stock's severe decline merits scrutiny into whether he sees genuine value or is simply catching a falling knife.

CEO Kersten buys 38,023 shares of CVM at $5.26 (+45.9% position growth); cross-ticker record shows avg 90d return +1217.4%, but prior CVM buys show mixed recent timing.

Gerrit Kersten, Chief Executive Officer, purchased 38,023 shares worth $200,000.98 at $5.26 per share on 2026-01-22, expanding his holdings by 45.9% to 120,815 shares. His cross-ticker track record across all open-market buys shows an average 90-day return of +1217.4% with a 100% win rate across 3 prior trades, indicating a consistent pattern of well-timed accumulations. However, this company-specific signal is tempered by recent CVM history: his December 2025 buy at this same ticker has declined 13.6% over 30 days (outcome not yet fully measurable at 90 days), and while his July 2025 CVM purchase returned +31.2% over 90 days, the stock now trades at $6.18—down 59.8% from its 52-week high of $15.38—despite the company reporting +65.4% annual revenue growth. The disconnect between strong CEO accumulation, impressive historical timing skill, and the company's unprofitable fundamentals ($-5.7M net income in the latest quarter on $77.4K quarterly revenue) and recent stock weakness warrants investor attention to whether this CEO conviction aligns with sustainable business trajectory.

CEL SCI CEO Kersten bought 8,389 shares at $5.96; stock down -71.9% from 52-week high, -38.5% in 90 days. Prior CVM buys showed +31.2% and +2403.6% 90-day returns.

CEO Kersten invested approximately $49,998.44 to purchase 8,389 shares at $5.96, increasing holdings by 11.4% to 81,794 shares. The purchase occurs while the stock trades at $6.45, down -71.9% from its 52-week high of $22.95 and -38.5% over the past 90 days. Materially, the company is unprofitable with net income of $-5,664,704.00 on quarterly revenue of $77,403.00, though annual revenue growth reached +65.4%. Notably, Kersten's two prior open-market buys at CVM were both well-timed at the 90-day mark, with returns of +2403.6% and +31.2%, establishing a pattern of purchase discipline at this specific ticker. This latest purchase arrives after a substantial drawdown and follows the insider's documented history of recognizing inflection points.

Director Watson buys 2,919 shares of CEL SCI at $6.85 (July 25), expanding stake 358.6%; prior buy at ticker netted +2705.8% in 30 days.

Robert Eugene Watson, a company director, purchased 2,919 shares at $6.85 on 2025-07-25, increasing his total holdings from 814 to 3,733 shares—a 358.6% expansion of his pre-transaction position. His timing appears disciplined: his one prior purchase at CVM (2024-05-08) generated a 30-day return of +2705.8% and 90-day return of +2403.6%, indicating successful entry execution at this ticker in the past. The current price of $7.15 sits -82.4% from the 52-week high of $40.50, though the stock has risen +197.9% over the prior 30 days. The company remains unprofitable (net income of $-6,572,389.00 for the latest full year) with minimal quarterly revenue ($77,403.00 in the most recent quarter), placing this purchase in the context of a loss-making enterprise that has nonetheless demonstrated extreme volatility. The director's reinvestment at depressed valuations relative to recent highs, paired with his demonstrated prior success at this ticker, merit close monitoring for the conviction signal implied by position expansion.

CEO Geert Kersten buys 29.2K shares of CVM at $6.85 ($200.0K), increasing stake 66.9%; stock up 258.8% in 30 days, -80.1% from 52-week high.

CEO Geert Kersten purchased 29,197 shares at $6.85 on 2025-07-25, representing a material 66.9% increase to his holdings and a substantial $200.0K commitment. His prior buy at CVM on 2024-05-08 posted a 90-day return of +2403.6%, establishing a pattern of well-timed purchases at this ticker. The current market context is volatile: the stock has surged 258.8% in the past 30 days but remains 80.1% below its 52-week high of $43.20, suggesting recovery from a severe drawdown. Fundamentally, the company is unprofitable (full-year net income of $-6,572,389.00) despite strong annual revenue growth of 65.4%, creating a typical biotech profile of high growth without current profitability. The timing and scale of this insider purchase merit scrutiny given the extreme price volatility and the CEO's demonstrated accuracy in prior CVM entry points.